ABSTRACT Human normal and sickle red blood cells (RBCs) adhere with high affinity to the alpha5 chain of laminin (LAMA5) via the basal cell adhesion molecule/Lutheran (BCAM/Lu) receptor, which is implicated in vasoocclusive episodes in sickle cell disease and activated through the cyclic adenosine monophosphate (cAMP) signaling pathway. However, the effect of the cAMP pathway on the expression of active BCAM/Lu receptors at the single-molecule level is unknown. We established an in vitro technique, based on atomic force microscopy, which enables detection of single BCAM/Lu proteins on the RBC surface and measures the unbinding force between BCAM/Lu and LAMA5. We showed that the expression of active BCAM/Lu receptors is higher in homozygous sickle RBCs (SS-RBCs) than normal RBCs and that it is critically dependent on the cAMP signaling pathway on both normal and SS-RBCs. Of importance, we illustrated that A-kinase anchoring proteins are crucial for BCAM/ Lu receptor activation. Furthermore, we found that SS-RBCs from hydroxyurea-treated patients show a lower expression of active BCAM/Lu receptors, a lower unbinding force to LAMA5, and insignificant stimulation by epinephrine as compared to SS-RBCs from untreated patients. To our knowledge, these findings may lead to novel antiadhesive targets for vasoocclusive episodes in sickle cell disease.
INTRODUCTION
Red blood cells (RBCs) express several surface adhesion receptors known to modulate cellular physiology (1, 2) . In sickle cell disease (SCD) (3, 4) , cytoadherence of RBCs to the alpha5 chain of endothelial laminin (LAMA5) via the basal cell adhesion molecule/Lutheran (BCAM/Lu) receptor is thought to be a major contributor to and possibly the primary cause of vasoocclusive episodes (VOEs) (5, 6) . On normal and homozygous sickle RBCs (SS-RBCs), the activation of adhesion receptors can be modulated by hormones such as epinephrine (7, 8) , pharmaceutical drugs such as hydroxyurea (HU) (9, 10) , and other biochemical stimuli (11) . Because SCD patients have extensive endothelial damage (12) and elevated plasma levels of laminin (13) , RBC adhesion studies have focused on the specific interaction between BCAM/Lu and LAMA5, a component of the subendothelial matrix (14) (15) (16) . Although it is known that this interaction is mediated by cyclic adenosine monophosphate (cAMP) (8) , the effects of the cAMP signaling pathway on the expression of BCAM/Lu receptors and on the interaction between BCAM/Lu and LAMA5 at the single-molecule level are unknown. Furthermore, it is unknown if scaffold or anchoring proteins, such as A-kinase anchoring proteins (AKAPs) (17) , play a role in BCAM/ Lu receptor activation. It is also unknown, at the singlemolecule level, if treatment with HU modulates BCAM/ Lu receptor expression or modifies the strength of the bond between BCAM/Lu and LAMA5.
In this work, we employed single-molecule atomic force microscopy (AFM) (7, 18, 19) to quantitatively study the modulation of BCAM/Lu expression on the membrane of normal and SS-RBCs. Single-molecule AFM measures the unbinding force between a specific ligand and its corresponding receptor on a single cell with piconewton sensitivity (20) (21) (22) (23) . We detected the unbinding force between BCAM/Lu and LAMA5, which is interpreted as adhesive force. The generated data are used to calculate the expression of active BCAM/Lu receptors on the RBC surface and their spatial distribution on the membrane at high resolution (~30 nm) (7, 20, 24) .
Previous experimental approaches using flow adhesion assays (8) have shown that in SS-RBCs, the interaction between BCAM/Lu and LAMA5 is strongly mediated by cAMPdependent protein kinase A (PKA) (8, 15) . Stimulation of the b2-adrenergic receptor (b2-AR) (25, 26) activates the G-protein coupled receptor Gas, which stimulates adenylyl cyclase (AC) (27) . AC then catalyzes the conversion of ATP to cAMP, resulting in PKA activation and ensuing BCAM/Lu-laminin adhesion. Normal RBCs, however, adhere minimally to the vascular endothelium (2) and their response to stimulation by epinephrine or forskolin (FSK) has not been detected by flow adhesion experiments (8) .
Here, by using a single-molecule assay, we clearly detected variability in the expression of BCAM/Lu on normal and SS-RBCs as it is modulated by the cAMP signaling pathway.
It is currently unknown if the scaffold protein AKAPs (17) play a role in BCAM/Lu receptor activation by localizing PKA activity to specific subcellular domains within RBCs. In other cell types, it has been found that PKA activity is localized within the cell by attachment of the PKA molecule to an AKAP. Specifically, a PKA tetrameric holoenzyme (28) , consisting of two catalytic and two regulatory subunits, binds to an AKAP via its regulatory subunits. The resultant PKA/AKAP complex is localized to a unique subcellular domain due to the AKAP-specific targeting domain (25, 29) . In this work, we showed that AKAPs mediate the activation of BCAM/Lu by PKA in RBCs, signifying that cAMP activates PKA locally, close to the cell membrane.
Hillery et al. (9) first demonstrated that SS-RBCs from patients receiving HU undergo a decrease in adhesion to LAMA5. This finding was contrasted by another result (30) showing that the expression of BCAM/Lu receptors on SS-RBCs from HU-treated patients increased. A resolution to this conflicting evidence was offered by a recent work, which demonstrated that the reduced adhesion of SS-RBCs to LAMA5 is likely due to inhibition of BCAM/ Lu phosphorylation by HU (10) . However, it is still unclear if the lower adhesion is only due to the reduced expression of active BCAM/Lu receptors as a result of inhibition of BCAM/Lu phosphorylation, or if HU also affects the unbinding force between BCAM/Lu and LAMA5. In our experiments, we measured the expression and unbinding force to LAMA5 of active BCAM/Lu receptors on SSRBCs from untreated and HU-treated patients. We found that both the expression and adhesive force of active BCAM/Lu molecules is decreased in HU-treated patients. These data demonstrate a very beneficial effect of HU in reducing the propensity of SS-RBCs to adhere to LAMA5.
In summary, we employed single-molecule AFM to investigate interactions between RBCs and the endothelium, and their regulation via cAMP. We quantified cAMP-dependent modulation of active BCAM/Lu receptor expression in normal and SS-RBCs. To our knowledge, we are first to demonstrate that AKAPs are crucial for the activation of BCAM/Lu receptors. Finally, we showed that HU treatment results in decreased erythrocyte adhesion to the endothelium due to lower expression of BCAM/Lu receptors and lower binding forces between BCAM/Lu and LAMA5.
METHODS

Patients and blood samples
Homozygous SCD patients (SS) at steady state, and age-/race-matched healthy volunteers at least 18 years of age were eligible to participate in this study, which was approved by the Institutional Review Boards of the UCONN Health Center and UCONN-Storrs. Individuals with SCD were eligible to participate if they had not been transfused in R3 months and were not having an acute VOE, suggesting a phenotype of milder severity. A complete blood count test was obtained for each patient. The untreated patients averaged HbF concentrations of 9.6 5 4.0% (range: 0%-18.2%), whereas HU-treated patients averaged 34.1% (range: 18.1%-56.1%). Reticulocyte percentages averaged 10.8 5 2.0% (range: 4.2%-15.7%) for untreated patients and 4.1 5 0.9% (range: 2.3%-6.7%) for HU-treated patients. Healthy volunteers were eligible to participate if they did not have a blood disorder or hemoglobinopathy, which was confirmed by screening blood samples via hemoglobin electrophoresis. Experiments were performed using fresh-drawn, heparin-anticoagulated venous blood.
Red blood cell preparation
Whole blood was centrifuged at 500 Â g for 10 min at 4 C to isolate RBCs. The buffy coat was aspirated and discarded. RBCs were washed 3Â with Alsever's solution. RBCs were immobilized by incubation on a poly-llysine-coated glass petri dish for 10 min at 37 C and unattached RBCs were removed by rinsing.
Reagents
Human laminin subunit alpha-5 (LAMA5) was obtained from MyBioSource (San Diego, CA), St-Ht31 inhibitor peptide and St-Ht31P control peptide (reconstituted in Alsever's solution) were obtained from Promega (Madison, WI). Alsever's solution, FSK (Coleus forskohlii) (reconstituted in DMSO), Rp-Adenosine 3 0 ,5 0 -cyclic monophosphorothioate triethylammonium salt (Rp-cAMPS; reconstituted in DMSO), KT-5720 (reconstituted in methanol), epinephrine (reconstituted in Alsever's solution), bovine serum albumin (BSA; reconstituted in PBS) were purchased from Sigma Aldrich (St. Louis, MO).
Preparation of LAMA5 probes
Silicon nitride cantilevers (Bruker Probes, Camarillo, CA) were silanized with 2% v/v 3-aminopropyltriethoxysilane in acetone (10 min), and then rinsed with deionized water and immersed in glutaraldehyde (0.5%, 30 min). Cantilevers were rinsed with deionized water, incubated in LAMA5 solution (100 mg/mL, 30 min), rinsed again, and incubated in BSA (100 mg/mL, 5 min) to block remaining aldehyde groups. Cantilevers were stored at 4 C and used within 48 h.
AFM assays
Force-distance curves were recorded between laminin-functionalized probes and BCAM/Lu receptors on the RBC surface ( Fig. 1 A) using the MFP-3D-BIO AFM (Asylum Research, Santa Barbara, CA). An unbinding force is defined as the maximum rupture force associated with the forcedistance curve. A representative curve highlighting regions of the approach and retraction cycle is shown in Fig. 1 B. On surface regions void of BCAM/ Lu receptors, we expected the unbinding force to be zero, although unbinding forces are significantly higher in regions where the laminin-functionalized cantilever made contact with active BCAM/Lu receptors. Unbinding forces were measured on 1 mm Â 1 mm areas of the RBC membrane with a lateral resolution of 31.25 nm (1024 sampled sites per experiment). To determine the spatial distribution of BCAM/Lu receptors on the RBC surface, unbinding forces were plotted as a force map (see Fig. 1 D) using MATLAB (The MathWorks, Natick, MA) in which the color of each square indicates the magnitude of the corresponding unbinding force obtained from an individual force-distance curve (7) . An inverted microscope (Zeiss Axiovert A1) was used to position the AFM cantilever in contact with a chosen RBC (Fig. 1 C) . Chosen RBCs were <10 mm in diameter and exhibited a distinct biconcave shape, suggesting RBC maturity. Experiments were performed in Alsever's solution at 37 C, and biochemical modulators were added at least 30 min before experiments (30 min: Epinephrine, FSK, KT-5720, Rp-cAMPS; 120 min: St-Ht31, StHt31P). For each assay, three RBCs were tested from each subject's blood. Values reporting N ¼ denote the number of unique donors per condition and n ¼ denote the total number of tested cells. Measurements
Biophysical Journal 106(6) 1258-1267 were recorded with a loading rate of 24,000 pN/s (7). The nominal spring constant of the employed cantilever was 30 pN/nm and the exact spring constant value was obtained via a thermal noise-based method and used in all calculations (31).
Statistical methods
Values for the unbinding force between BCAM/Lu and LAMA5 are reported as average 5 SD as determined by a frequency distribution fit with the Gaussian model (GraphPad Prism). In the frequency (%) distribution, each bin contains the number of unbinding forces with values within the bin's range divided by the total number of sampled sites. We note that the frequency of zero force points is not shown because it is much larger than the frequency of nonzero force points and would obscure the graphs. Collective frequency (%), denoted CF, is the frequency of active BCAM/ Lu surface receptors and is defined as the total number of all nonzero force points, without respect to specific unbinding forces, divided by the total number of sampled sites for each experimental condition. It is reported as average 5 SE and is illustrated by box-whisker plots. The collective frequency of active receptors was compared between groups using a oneway analysis of variance (ANOVA) with the Tukey post hoc test, and between two conditions using a two-tailed t-test. Results were considered significant if p<0.05.
RESULTS
Single-molecule measurement of active BCAM/Lu receptors on normal RBCs
We first performed experiments on normal RBCs in Alsever's solution to determine the baseline frequency (À bath laminin) of active BCAM/Lu receptors and the unbinding force of BCAM/Lu to LAMA5. The n on the x axis indicates the total number of mature RBCs analyzed in each group, obtained from the following numbers of human subjects: -Bath laminin: 4 subjects; þ Bath laminin, þ Epinephrine: 3 subjects. Significance relative to -bath laminin is denoted as * such that p < 0.05 and ** such that p < 0.005 (two-tailed t-test). To see this figure in color, go online.
Biophysical Journal 106(6) 1258-1267 shown in Fig. 1 E. By accumulating all of the nonzero unbinding forces per cell we obtained the collective frequency, as explained in the methods. The results, illustrated using a box-whisker plot, show that unbinding forces were detected in 3.31 5 0.67% of sampled sites (Fig. 1 F) .
To determine the specificity of measured unbinding forces, we repeated the experiments on normal samples preincubated with laminin. As shown in Figs. 1 D(ii) , F, the CF of events detecting unbinding forces on RBCs preincubated with laminin (þ bath laminin) was 0.89 5 0.21%, which is significantly lower (p < 0.01) than the baseline frequency (À bath laminin, CF: 3.31 5 0.67%). Recorded unbinding forces likely reflected BCAM/Lu receptors that were not bound by bath laminin. To establish that the assay can detect variations in the number of active BCAM/Lu receptors, we preincubated RBCs with epinephrine (1 mM), a b-AR agonist known to increase BCAM/Lu binding to LAMA5, and found that events were detected in 10.27 5 2.02% of sampled sites, a significant increase (p < 0.001) in the CF from baseline ( Fig. 1 D( iii), F). Frequency distributions (Fig. 1 E) show that although the average unbinding force between BCAM/Lu and LAMA5 did not change in these experimental conditions, the frequency of detected events changed significantly. Furthermore, the data in Fig. 1 (Fig. S1 in the Supporting Material). Previous evidence suggests that the interaction between BCAM/Lu and LAMA5 is stimulated significantly by FSK in SS-RBCs but insignificantly in normal RBCs (8) . These studies used a FSK concentration (80 mM) much higher than that currently used (30 mM). To understand the discrepancy between ours and previous results, we used the higher concentration of FSK employed in the previous study (8) . In this case, we found that the interaction between BCAM/Lu and LAMA5 was stimulated (data not shown; CF: 10.10 5 1.89%, N ¼ 3, n ¼ 9) significantly more than normal RBCs at baseline (p < 0.05), albeit not significantly more than those treated with 30 mm FSK. It is possible that flow adhesion assays, which measure the average adhesion of a large number of erythrocytes to a functionalized-substrate under flow-induced shear stress, are not sensitive enough to detect increases in the overall low adhesion of normal RBCs.
To quantify the effect of PKA inhibition on the frequency of active BCAM/Lu receptors, we treated RBCs with Rp-cAMPS (100 mM), a strong inhibitor of PKA activation by cAMP. RBCs pretreated with Rp-cAMPS exhibited fewer unbinding events (Fig. 2 , B and C; CF: 1.17 5 0.47%) than normal RBCs at baseline. An apparent decrease in the unbinding force following preincubation with RpcAMPS compared to baseline results is statistically insignificant. Next, we directly inhibited PKA using KT-5720 (1 mM) and recorded a decrease in the unbinding event frequency (Fig. 2 , B and C; CF: 2.16 5 0.41%), albeit not as large as with Rp-cAMPS. Fig. 2 C shows a box-whisker plot summarizing changes in the collective frequency of active BCAM/Lu receptors on normal RBCs in response to cAMP-dependent pathway modulation. It is clear that there is a significant increase in the collective frequency of active BCAM/Lu receptors resulting from 30 mM FSK, demonstrating that our system can detect changes in the adhesive properties of human RBCs in response to increases in intracellular cAMP.
SS-RBCs demonstrate greater PKA-dependence of BCAM/Lu adhesion to endothelial laminin than normal RBCs
After establishing our single-molecule AFM technique on normal RBCs and confirming that we can detect differences in the frequency of active BCAM/Lu in response to cAMPdependent pathway modulators, we applied the same experimental approach to SS-RBCs. In agreement with previous reports (2,8), we measured a significant increase in the frequency of BCAM/Lu receptors on SS-RBCs (Fig. 3, A and E; CF: 8.89 5 2.05%) as compared to normal RBCs (p < 0.01). Next, we quantified changes in the frequency of active BCAM/Lu receptors on SS-RBCs in response to cAMPdependent pathway modulation. Following preincubation with FSK (30 mM), we observed an increase in the CF to 20.56 5 3.63% on SS-RBCs, which was significantly greater than that measured at baseline (Fig. 3 E; p < 0.01) and similar to that observed on normal RBCs (Fig. 3 B) . Of importance, when treated with Rp-cAMPS, the adhesion level of SS-RBCs reduced to that of normal RBCs treated with Rp-cAMPS. However, preincubation with KT-5720 (see Fig. 3 D) did not decrease the BCAM/Lu receptor frequency on SS-RBCs to the adhesion level of normal RBCs, but still significantly decreased below the baseline Biophysical Journal 106(6) 1258-1267 measurement to 2.66 5 1.02% (Fig. 3 E; p < 0.05). Frequency distributions illustrate that the response to modulation of BCAM/Lu on SS-RBCs was analogous to that on normal RBCs (Fig. 3, B-D) . Furthermore, the collective frequency of detected BCAM/Lu receptors was highly sensitive to cAMP-dependent pathway modulators (Fig. 3 E) . Table 1 presents specific unbinding forces (mean 5 SD) and collective frequencies (mean 5 SE) for normal and SS-RBCs.
AKAPs regulate BCAM/Lu adhesion
After establishing that our assay can detect cAMP-dependent modulation of active BCAM/Lu receptors on normal and SS-RBCs, we investigated the possibility of localized BCAM/Lu activation via AKAPs (25, 29) . To detect the presence of AKAPs on normal and SS-RBCs, cells were treated with St-Ht31 peptide (5 mM), which inhibits binding of PKA to AKAPs. Our experiments revealed that following pretreatment with St-Ht31, the CF of active BCAM/Lu receptors decreased significantly in normal RBCs (Fig. 4 , A and B; CF: 5.71 5 1.23% to 1.63 5 0.39%; p < 0.05) and in SS-RBCs (Fig. 4 , C and D; CF: 7.19 5 1.42% to 2.02 5 0.37%; p < 0.005). As a negative control, RBCs were pretreated with St-Ht31P control peptide (5 mM), which did not alter the collective frequency of active BCAM/Lu receptors in normal RBCs (Fig. 4 B; CF: 5.92 5 1.09%) or in SS-RBCs (Fig. 4 D; (Fig. 4 B; (Fig. 4 D; p < 0.005) . This indicates the presence of AKAPs in the RBC membrane and suggests their importance in the mediation of RBC cytoadherence to the endothelium in both normal and SS-RBCs. Table 2 presents specific unbinding forces (mean 5 SD) and collective frequencies (mean 5 SE) for normal and SS-RBCs.
HU decreases the frequency and the strength of BCAM/Lu-dependent adhesion events on SSRBCs
HU is currently the only pharmacologic treatment to reduce the frequency of VOEs in SCD, yet only two-thirds of patients respond favorably to the drug (32) . The drug has been found to inhibit phosphorylation of BCAM/Lu receptors and consequently to decrease SS-RBC adhesion to laminin (9, 10) . Here, we investigated the quantitative effect of HU treatment on the frequency of active BCAM/Lu receptors and on the magnitude of the unbinding force between BCAM/Lu and LAMA5, which could be another reason for the reduced adhesion of SS-RBCs to laminin. Our experiments showed for the first time, to our knowledge, that SS-RBCs from HU-treated patients have a significantly lower frequency of active BCAM/Lu receptors than SS-RBCs from untreated patients (Fig. 5 A; CF: 8.89 5 2.05% to 2.43 5 0.51%; p < 0.001). Of importance, we also detected that the unbinding force between BCAM/Lu and LAMA5 was lower on SS-RBCs from HU-treated patients (Fig. 5 B; CF: 35.14 5 7.18 pN vs. 40.00 5 8.12 pN; p < 0.0001). Differences in the unbinding force of BCAM/Lu and laminin resulting from HU treatment have not previously been reported. Next, the physiologic implication of epinephrine-stimulated adhesion of HU-treated SS-RBCs was studied. We treated SS-RBCs with epinephrine and found that for SS-RBCs from patients undergoing HU-treatment, the frequency of BCAM/Lu did not increase significantly. Fig. 5 C shows that although the CF of BCAM/ Lu receptors increased significantly following treatment with epinephrine on both normal RBCs and untreated SS-RBCs, there was no significant increase in HU-treated SS-RBCs.
DISCUSSION
In this work, we established a technique, based on AFM, which enables the detection of single BCAM/Lu molecules on the RBC surface and measures the unbinding force between BCAM/Lu and LAMA5. The technique is used to study the effect of the cAMP signaling pathway on the activation of BCAM/Lu receptors at the single-molecule level. Of importance, we demonstrate that AKAPs are essential for BCAM/Lu receptor activation, and that the collective frequency of BCAM/Lu receptors, present on both the normal and SS-RBC membrane, is critically dependent on the cAMP pathway. Finally, we found that SS-RBCs from HU-treated patients have a lower frequency of active BCAM/Lu receptors than SS-RBCs from untreated patients, and undergo insignificant stimulation by epinephrine. We also demonstrated that the unbinding force between BCAM/Lu and LAMA5 in HU-treated patients is lower than in untreated patients.
cAMP-dependent modulation of BCAM/Lu on normal RBCs
We first determined how the frequency of active BCAM/Lu receptors changes in response to cAMP signaling. FSK activates AC, which raises levels of cAMP and subsequently activates the cAMP-dependent pathway. Normal RBCs treated with FSK (30 mM) showed an increase in the frequency of active BCAM/Lu receptors significantly above baseline, in accordance with established cAMP-dependent pathway modulation. However, previous studies based on flow adhesion assays showed that adhesion of normal RBCs via BCAM/Lu is not mediated significantly by FSK, likely due to low levels of intracellular cAMP (8) . In contrast, our results indicate that normal RBC adhesion to LAMA5 via the BCAM/Lu receptor is significantly modulated by the cAMP-dependent pathway. This difference is due to two reasons. First, previous studies used a FSK concentration of 80 mM, which is >2Â greater than the concentration we initially employed ( than traditional flow adhesion assays. We also note that flow adhesion assays did not detect adhesion of nonstimulated normal RBCs to laminin (8, 10) .
cAMP-dependent modulation of BCAM/Lu on SSRBCs
Although the pathway by which cAMP mediates BCAM/Lu receptor activation is well-established, the possibility that AKAPs are involved in the localization of cAMP close to the RBC membrane has not been investigated. In the current work, we used specific biochemical modulators to investigate the subcellular targeting of the cAMP-dependent PKA (28) . PKA activity can be mediated by AKAPs, which sequester PKA to specific subcellular sites through binding to its regulatory subunits (25, 29, 36) . Each AKAP contains two classes of binding sites: an anchoring motif, which binds to the regulatory subunit of PKA, and a targeting domain, which directs the subcellular localization of the PKA-AKAP complex through association with structural proteins, membranes, or other cell elements (29) . BCAM/ Lu-mediated SS-RBC adhesion to LAMA5 is activated by the phosphorylation of serine 621 in the BCAM/Lu cytoplasmic domain, but this phosphorylation does not occur as readily in normal RBCs (15) . We conjecture that this is due to the presence of more PKA-AKAP complexes in SS-RBCs, and resultant AKAP assistance in the phosphorylation of BCAM/Lu on RBCs. Furthermore, because protein activation is highly selective despite the high cAMP diffusion constant of 270-280 mm 2 /s, it is likely that the cAMP is compartmentalized (37, 38) and has a basal effect on normal RBCs, which only requires increases in cAMP near the membrane. This may explain why we detected modulation of BCAM/Lu via the cAMP-dependent pathway despite low levels of cAMP in normal RBCs (8) .
HU reduces the adhesion of SS-RBCs via the BCAM/Lu receptor HU, a pharmacologic treatment for SCD VOEs, is known to stimulate an increase in HbF (39, 40) synthesis, and may also alter RBC signaling (9, 10, 41) . The drug has been found to decrease SS-RBC adhesion to laminin (9,10), although it increases BCAM/Lu surface expression (10, 30) . Hillery et al. (9) first demonstrated that RBCs from SCD patients receiving HU undergo a decrease in adhesion to laminin. Recently, it was shown that although BCAM/Lu receptor expression is increased on SS-RBCs from HU-treated patients, SS-RBC adhesion to laminin is decreased because of inhibition of cAMP phosphorylation (10, 30) . In our experiments, we measured a lower frequency of active BCAM/Lu receptors on SS-RBCs from HU-treated patients versus SS-RBCs from untreated patients. In addition, AFM measurements revealed a lower unbinding force between BCAM/Lu on SS-RBCs from HU-treated patients with LAMA5 as compared to untreated patients. The lower unbinding forces between BCAM/Lu and LAMA5 in conjunction with the lower frequency of active BCAM/Lu receptors on SS-RBCs from HU-treated patients demonstrate the beneficial effect of HU in reducing SS-RBC adherence to LAMA5, a mechanism thought to be critical to VOE genesis.
To determine the physiological implications of cAMPstimulated adhesion of HU-treated RBCs, we preincubated SS-RBCs from untreated and HU-treated patients with epinephrine, a hormone released during stress and known to stimulate the b2-AR (7, 8) . Our results indicate that epinephrine does not significantly increase the frequency of active BCAM/Lu receptors on the surface of SS-RBCs from HU-treated patients. Furthermore, because we did not detect a difference in the unbinding force or the receptor frequency, we conjecture that HU modifies the b2-AR pathway thereby reducing the ability for epinephrine-stimulation. Consistent with previous studies related to the phenotypic variability of SCD (8), we also found that the patient response to epinephrine was variable.
A determinant of clinical phenotype in SCD is the adhesive properties of RBCs, defined by the subcellular density and distribution of adhesion receptors, and the unbinding force associated with specific ligands. In this Significance is denoted as * such that p < 0.05 and ** such that p < 0.005 as computed using the t-test. To see this figure in color, go online.
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work, single-molecule AFM was employed to quantify the response to cAMP-dependent pathway modulation via measurement of specific ligand-receptor unbinding forces and the CF of active adhesion receptors on the RBC. From the perspective of cell mechanics and especially of cell mechanics and cell adhesion modeling, our data are significant because they can be used to set the parameters for the simulations. Of importance, we detected the presence of AKAPs on the membrane of both normal and SS-RBCs, and revealed that these proteins play a significant role in the modulation of BCAM/Lu via the cAMP pathway. Finally, we demonstrated that HU-treatment reduces the ability for stimulation by epinephrine suggesting that HU modifies the b2-pathway. The study shows new, to our knowledge, important implications for AFM cytoadhesion assays in evaluating the pharmacologic response of adhesion receptors on RBCs.
SUPPORTING MATERIAL
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